Business Context and Reporting Period
This Form 8-K Current Report was filed by Black Diamond Therapeutics, Inc. (BDTX) on January 18, 2024, covering events occurring on January 17, 2024. The company is a Delaware corporation with its principal executive offices in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statement data.
Material Changes
The primary material change reported is the departure of a director:
- Rajeev Shah resigned from the Board of Directors and his position as a member of the Audit Committee, effective immediately on January 17, 2024.
- Mr. Shah had served on the Board since December 2018.
- The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the director's resignation.
Investor Verification Checklist
- Confirm the effective date of Rajeev Shah's resignation (January 17, 2024).
- Verify the composition of the Board of Directors and Audit Committee following this departure.
- Review subsequent filings to determine if a replacement director has been appointed.
- Check for any related press releases or investor communications regarding the resignation.